Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Control Release ; 152(1): 76-83, 2011 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-21277920

RESUMO

Multidrug resistance (MDR) is characterized by the overexpression of ATP-binding cassette (ABC) transporters that actively pump a broad class of hydrophobic chemotherapeutic drugs out of cancer cells. MDR is a major mechanism of treatment resistance in a variety of human tumors, and clinically applicable strategies to circumvent MDR remain to be characterized. Here we describe the fabrication and characterization of a drug-loaded iron oxide nanoparticle designed to circumvent MDR. Doxorubicin (DOX), an anthracycline antibiotic commonly used in cancer chemotherapy and substrate for ABC-mediated drug efflux, was covalently bound to polyethylenimine via a pH sensitive hydrazone linkage and conjugated to an iron oxide nanoparticle coated with amine terminated polyethylene glycol. Drug loading, physiochemical properties and pH lability of the DOX-hydrazone linkage were evaluated in vitro. Nanoparticle uptake, retention, and dose-dependent effects on viability were compared in wild-type and DOX-resistant ABC transporter over-expressing rat glioma C6 cells. We found that DOX release from nanoparticles was greatest at acidic pH, indicative of cleavage of the hydrazone linkage. DOX-conjugated nanoparticles were readily taken up by wild-type and drug-resistant cells. In contrast to free drug, DOX-conjugated nanoparticles persisted in drug-resistant cells, indicating that they were not subject to drug efflux. Greater retention of DOX-conjugated nanoparticles was accompanied by reduction of viability relative to cells treated with free drug. Our results suggest that DOX-conjugated nanoparticles could improve the efficacy of chemotherapy by circumventing MDR.


Assuntos
Antibióticos Antineoplásicos/administração & dosagem , Neoplasias Encefálicas/tratamento farmacológico , Doxorrubicina/administração & dosagem , Compostos Férricos/administração & dosagem , Glioma/tratamento farmacológico , Nanopartículas Metálicas/administração & dosagem , Animais , Linhagem Celular Tumoral , Doxorrubicina/química , Doxorrubicina/farmacocinética , Resistência a Múltiplos Medicamentos , Resistencia a Medicamentos Antineoplásicos , Compostos Férricos/química , Concentração de Íons de Hidrogênio , Nanopartículas Metálicas/química , Tamanho da Partícula , Polietilenoglicóis/química , Polietilenoimina/química , Ratos , Solubilidade , Distribuição Tecidual
2.
Mol Pharm ; 7(6): 1930-9, 2010 Dec 06.
Artigo em Inglês | MEDLINE | ID: mdl-20722417

RESUMO

A small interfering RNA (siRNA) nanovector with dual targeting specificity and dual therapeutic effect is developed for targeted cancer imaging and therapy. The nanovector is composed of an iron oxide magnetic nanoparticle core coated with three different functional molecules: polyethyleneimine (PEI), siRNA, and chlorotoxin (CTX). The primary amine group of PEI is blocked with citraconic anhydride that is removable at acidic conditions, not only to increase its biocompatibility at physiological conditions but also to elicit a pH-sensitive cytotoxic effect in the acidic tumor microenvironment. The PEI is covalently immobilized on the nanovector via a disulfide linkage that is cleavable after cellular internalization of the nanovector. CTX as a tumor-specific targeting ligand and siRNA as a therapeutic payload are conjugated on the nanovector via a flexible and hydrophilic PEG linker for targeted gene silencing in cancer cells. With a size of ∼60 nm, the nanovector exhibits long-term stability and good magnetic property for magnetic resonance imaging. The multifunctional nanovector exhibits both significant cytotoxic and gene silencing effects at acidic pH conditions for C6 glioma cells, but not at physiological pH conditions. Our results suggest that this nanovector system could be safely used as a potential therapeutic agent for targeted treatment of glioma as well as other cancers.


Assuntos
Inativação Gênica/efeitos dos fármacos , Glioma/tratamento farmacológico , Glioma/genética , Nanopartículas/toxicidade , RNA Interferente Pequeno/toxicidade , Animais , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Meios de Contraste/química , Meios de Contraste/toxicidade , Compostos Férricos/química , Compostos Férricos/toxicidade , Glioma/patologia , Concentração de Íons de Hidrogênio , Imageamento por Ressonância Magnética , Magnetismo , Estrutura Molecular , Nanopartículas/química , Tamanho da Partícula , Polietilenoimina/química , Polietilenoimina/toxicidade , RNA Interferente Pequeno/química , Venenos de Escorpião/química , Venenos de Escorpião/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...